A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

• Status: Completed
• Trial end date: 2015-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca; Eli Lilly and Company
• Collaborators: AstraZeneca; Eli Lilly and Company
• Treatments: Donepezil; Midazolam; Simvastatin

Criteria

Inclusion Criteria:

• Overtly healthy and either sterile or, male and prepared to use an approved method of contraception

• Have a body mass index (BMI) at screening of 19.0 to 32.0 kilogram per square meter (kg/m^2)

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the results, or may limit the subject's ability to participate in the study

• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs

• History of previous or ongoing psychiatric disease/condition